Literature DB >> 2310055

Management of multiple cholesterol embolization syndrome--a case report.

Y Kawakami1, K Hirose, Y Watanabe, N Tomioka, K Doyama, M Morikawa, K Kosuga, T Saiga.   

Abstract

A sixty-two-year-old man who underwent coronary angiography and received acute thrombolytic and anticoagulant therapy for acute myocardial infarction developed multisystemic injury, including renal insufficiency and cutaneous manifestations. Fundoscopic examination and skin biopsy specimen led to the diagnosis of multiple cholesterol embolization syndrome (MCES). Discontinuation of anticoagulants and administration of hemostatic (carbazochrome, tranexamic acid, reptilase, and vitamin K) and antihyperlipidemic (cholestyramine and probucol) drugs resulted in temporary improvement of cutaneous and renal disorders and extended survival for about one year. Besides severe aortic atherosclerosis, postmortem examination revealed numerous cholesterol emboli to multiple organs. MCES is a rare but serious complication of left heart catheterization and anticoagulant therapy, and the optimal treatment remains to be established. The authors suggest here that the above-mentioned therapy might be effective for management of MCES.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310055     DOI: 10.1177/000331979004100311

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  4 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

2.  How common is cholesterol embolism?

Authors:  S S Cross
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

3.  Cholesterol emboli syndrome--uncommon or unrecognized?

Authors:  S P Bell; A Frankel; E A Brown
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

Review 4.  Cholesterol embolisation after thrombolytic therapy.

Authors:  J C Blankenship
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.